bioMerieux SA · EURONEXT:BIM

bioMerieux SA — FY2019 Earnings Presentation

31 slides from bioMerieux SA's earnings presentation, Feb 26, 2020

  1. Slide 1: FY2019 Results & 2020 Outlook

    FY2019 Results & 2020 Outlook Investor Presentation – February 26th, 2020 PIONEERING DIAGNOSTICS

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains information, assumptions and estimates that were used by the Company to determine its objectives on a reasonable basis. They are subject to change or modification due to economic, financial, medical and competitive uncertainties in markets addressed by bioMérieu

  3. Slide 3: Agenda

    AGENDA > OVERVIEW OF BIOMERIEUX FY2019 STRATEGY REVIEW FY2019 FINANCIAL RESULTS 2020 OUTLOOK

  4. Slide 4: bioMérieux at a glance

    bioMérieux at a glance + 55 YEARS CLINICAL APPLICATIONS OF EXPERTISE IN INDUSTRIAL APPLICATIONS 83% of revenues IN VITRO DIAGNOSTICS 17% of revenues Sales amounting to 92% €2.7 billion of international sales About Strong commitment 1,800 people 12,000 to innovation14% dedicated to R&D employees worl

  5. Slide 5: bioMérieux: mission, strategy and strengths

    bioMérieux: mission, strategy and strengths PIONEERING DIAGNOSTICS to improve public health, especially in the fight against infectious diseases. MICROBIOLOGY MOLECULAR BIOLOGY IMMUNOASSAYS Maintain leadership positions Own the rapidly growing market of Reinforce specialty positioning in both clinic

  6. Slide 6: Solutions to manage infectious diseases and improve patient care

    bioMérieux provides solutions to manage infectious diseases and improve patient care Antimicrobial Protecting resistance consumers' health Respiratory Sepsis & infections emergency care 6

  7. Slide 7: Agenda

    AGENDA OVERVIEW OF BIOMERIEUX > FY2019 STRATEGY REVIEW FY2019 FINANCIAL RESULTS 2020 OUTLOOK

  8. Slide 8: Key takeaway messages: solid performance in 2019

    KEY TAKEAWAY MESSAGES solid performance in 2019, in line with objectives > SALES < > PROFITABILITY < > KEY GROWTH DRIVERS < €2,675m €389m Molecular biology +7.2% 14.5% Microbiology at constant exchange rates and of sales scope of consolidation vs. 15.0% in 2018 ASPAC region M&A BIOFIRE® CASH FLOW 

  9. Slide 9: Antimicrobial resistance: a reaffirmed leadership

    ANTIMICROBIAL RESISTANCE a reaffirmed leadership FIGHTING ANTIMICROBIAL RESISTANCE IS EVERYONE’S CONCERN  Fighting AMR is at the heart of bioMérieux’s mission  80% of sales and 75% of R&D investments dedicated to products that may directly or indirectly help healthcare professionals to fight AMR 

  10. Slide 10: BIOFIRE FILMARRAY sales

    MOLECULAR BIOLOGY BIOFIRE® leading the syndromic testing market +20% 10,400 units Installed base from 8,200 to Customers from 2,600 to 3,500 +37% Sales outside USA from 17% to 19% +50% New Proprietary Laboratory Analyses codes BIOFIRE® FILMARRAY ® sales 605 +60% 483 Future growth drivers 368 +80% 24

  11. Slide 11: Molecular biology: enriched syndromic menu, BCID 2 panel

    MOLECULAR BIOLOGY an enriched syndromic menu, with improved BCID 2 panel Respiratory BIOFIRE® BCID 2 (1) Panels Sepsis affects about 49 million patients and kills Pneumonia 11 million people every year (2) Panels Survival rate decreases significantly with every hour delay of effective antibiotics th

  12. Slide 12: Immunoassays: towards a reinforced portfolio of solutions

    IMMUNOASSAYS towards a reinforced portfolio of solutions CONTRASTED SITUATION INVESTING TO REVIGORATE GROWTH Increasing demand  Hybiome: in Middle-East, Africa and growing in Grade 2 hospitals in China Asia-Pacific  VIDAS® NEPHROCHECK®: available in H2 2020  VIDAS® Latent tuberculosis (IGRA*): cl

  13. Slide 13: Industrial microbiology: mixed performance in 2019

    INDUSTRIAL MICROBIOLOGY mixed performance in 2019 but solid fundamentals > SOLID FUNDAMENTALS < +5%  Increasing testing requirements to protect consumers and brands organic sales growth FOOD  Export from emerging countries driving more testing  Expansion of “fast methods” to improve  Performance

  14. Slide 14: Agenda

    AGENDA OVERVIEW OF BIOMERIEUX FY2019 STRATEGY REVIEW > FY2019 FINANCIAL RESULTS 2020 OUTLOOK

  15. Slide 15: FY2019 sales

    FY2019 sales Currency Change in scope of Organic effect consolidation growth + € 174m + € 53m + € 27m mainly Hybiome & +7.2% USD (1) + €56m Invisible Sentinel o/w > half from LatAm (2) - €10m BIOFIRE® Asia (3) + €8m €2,675m Metera (4) - €2m €2,421m + 10.5% 2018 2019 15 (1) Including HKD (2) ARS, BRL

  16. Slide 16: FY2019 sales by application

    FY2019 sales by application: solid growth supported by most strategic lines €36m 1% INDUSTRY +5% €467m MICROBIOLOGY +5% 17% €1,026m 38% GROUP €2,675m Clinical applications (83%) €672m  +7.2% +7.7% 25% MOLECULAR +18% €475m 18% IMMUNOASSAYS 0.4% 16

  17. Slide 17: FY2019 sales by geography

    FY2019 sales by geography: solid growth across all regions AMERICAS EMEA* ASIA PACIFIC €1,200m €961m €514m  +7.7%  +4.4%  +12.1% 45% 36% 19% GROUP €2,675m  +7.2% 17 * EMEA: Europe, Middle East, Africa

  18. Slide 18: FY2019 consolidated P&L: sales dynamics driving profitability

    FY2019 consolidated P&L: sales dynamics driving profitability improvement In €m 2019 As a % 2018 (1) As a % % change % change of sales of sales as reported at constant exchange rates and scope Net sales 2,675 100% 2,421 100% + 10.5% + 7.2% Cost of sales -1,208 -45.2% -1,119 -46.2% + 8.0% + 3.6% Gros

  19. Slide 19: FY2019 contributive operating margin

    FY2019 contributive operating margin: strong leverage offset by share plans & acquisitions +9.4% - € 43m + € 3m + € 77m - € 12m € 398m 15.3% € 389m 14.5% € 364m 15.0% 2018 (1) Operational Phantom share 2018 at CER FX Scope 2019 improvement plans and scope 19 (1) Restated to account for IFRS16

  20. Slide 20: FY2019 consolidated P&L: from operating income to EPS

    FY2019 consolidated P&L: from contributive operating income to EPS In €m 2019 As a % 2018 (1) As a % % change of sales of sales as reported Contributive operating income 389 14.5% 364 15.0% + 6.9% BioFire acquisition related costs - 18 - 18 Operating income 371 13.9% 346 14.3% + 7.1% Net financial e

  21. Slide 21: FY2019 tax rate

    FY2019 tax rate French tax rate 34.4% Foreign & reduced tax rates -6.8% -6.8%  Mainly due to US tax reform Tax credits -3.2% -3.2%  Mainly R&D Tax Credit FDII (1) -1.0% -1.0%  Implemented in 2019 Others (2) 0.5% 0.5% Recurring effective tax rate 24.2% Non-recurring items -1.7% -1.7%  Including 2

  22. Slide 22: FY2019 cash flow statement

    FY2019 cash flow statement -69 10% of sales  Manufacturing capacity increase for BIOFIRE® -102  Increase in instrument placements Leverage 0.5x EBITDA 578 -273 2018 net debt -267 as published 16 -48 -41 IFRS16 -13 -98 restatement Free Cash Flow (1) €-317m €150m €-365m Net debt as EBITDA WCR Income

  23. Slide 23: Agenda

    AGENDA OVERVIEW OF BIOMERIEUX FY2019 STRATEGY REVIEW FY2019 FINANCIAL RESULTS > 2020 OUTLOOK

  24. Slide 24: 2020 Outlook

    2020 OUTLOOK +5.0% to +7.0%  Uncertainties related to the impact of Covid-19 Revenues  at constant exchange rates epidemic & scope of consolidation  Higher flu season than in 2019  +5-10% organic growth Estimated €5-10m of negative FOREX impacts Contributive €395m to €415m    €10m negative im

  25. Slide 25: Covid-19 situation

    COVID-19 SITUATION  Current bioMérieux tests (FILMARRAY® and ARGENE®) do not detect Covid-19 like other existing coronavirus tests but can be used to rule out other causes of BIOMÉRIEUX respiratory infections SOLUTIONS  R&D work on-going to develop specific tests to detect Covid-19 / SARS-CoV-2 

  26. Slide 26: Organization: a new setup to tackle next growth cycle

    ORGANIZATION a new setup to tackle next growth cycle > KEY PRINCIPLES < LEVERAGE OUR UNIQUE VALUE-BASED OFFER DRIVE COMMERCIAL PERFORMANCE through focused organizations (Clinical Operations and Industry) FOSTER AGILE DECISION-MAKING taking into account local specificities while ensuring roll out of

  27. Slide 27: bioMérieux uniquely positioned to impact patient care

    bioMérieux is uniquely positionned to impact patient care in infectious diseases and consumer safety Comprehensive & complementary Increasing recognition solutions of the value of Diagnostics to address infectious diseases A sustainable culture and Simplified structure commitment to address major to

  28. Slide 28: Pioneering Diagnostics

    PIONEERING DIAGNOSTICS

  29. Slide 29: Recognized for its Corporate Social Responsibility policy

    bioMérieux is recognized for its Corporate Social Responsibility policy RESPONSIBILITY RESPONSIBILITY RESPONSIBILITY TO THE TO OUR WORKFORCE TO THE SOCIETY ENVIRONNEMENT Create an optimal working Help make diagnostics accessible, Reduce and control our environment through a commitment to address env

  30. Slide 30: Exposure and sensitivity to foreign currencies

    Exposure and sensitivity to foreign currencies FX impact of +/- 5% FX variation vs. EUR FX exposure Estimated impact of +/- 5% FX on contributive operating income on revenues variation vs EUR on contributive (2019 basis) operating income (1) Other emerging currencies €3m USD & related(2) 41% +/- € 5

  31. Slide 31: Contacts

    CONTACTS Ordinary shares (EUR) Sylvain MORGEAU ISIN: FR0013280286 Investor Relations bioMérieux is listed on Euronext Paris sylvain.morgeau@biomerieux.com Reuters: BIOX.PA / Bloomberg: BIM.FP +33 (0)6 01 27 56 46 American Depository Receipt (1:0.1 USD) Reuters: BMXXY.PK / Bloomberg: BMXXY.US Follow

bioMérieux — FY2019 Earnings Presentation on 6ix